Endo International plc
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Blaise Coleman
- Full Time Employees
- 3,103
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- Minerva House, Simmonscourt Road Dublin United States of America 4
- IPO Date
- Mar 3, 2014
- CIK
- 0001593034
- Website
- endo.com
- Similar Companies
- Business
- Endo International plc, an Ireland-domiciled specialty pharmaceutical company founded in 1997 and headquartered at First Floor, Minerva House, Simmonscourt Road, Ballsbridge, Dublin 4, Ireland, with U.S. headquarters in Malvern, Pennsylvania, develops, manufactures, markets and distributes branded and generic pharmaceuticals; its core products span Branded Pharmaceuticals including established brands such as XIAFLEX for Dupuytren's contracture and Peyronie's disease, BELBUCA for pain management, SUPPRELIN LA for central precocious puberty, and therapies in men's health, orthopedics and urology; Sterile Injectables encompassing a portfolio of injectable drugs; Generic Pharmaceuticals covering tablets, capsules, liquids, nasal sprays, ophthalmics and patches; and International Pharmaceuticals offering specialty products in Canada, Latin America and other regions. The company serves healthcare professionals and patients primarily in the United States and select international markets across therapeutic areas including endocrinology, gastroenterology, neurology, pulmonology, ophthalmology, rheumatology and critical care. In recent major developments, Endo International plc underwent financial restructuring, emerging from Chapter 11 bankruptcy in April 2024 as a private entity owned by its first-lien lenders following acquisition of its assets by Endo, Inc.; it completed a merger with Mallinckrodt plc on August 1, 2025, under which Endo shareholders received $100 million in cash and 49.9% ownership in the combined company with Mallinckrodt shareholders holding 50.1%; post-merger, the entity spun off its generics and sterile injectables businesses as independent Par Health while rebranding the branded pharmaceuticals operations as Keenova Therapeutics in November 2025, creating two focused companies with enhanced scale and operational efficiency.
Drugmakers Mallinckrodt, Endo to Merge, Plan NYSE Listing
Drugmaker Endo receives US court approval for bankruptcy restructuring
Drugmaker Endo reaches $465 mln bankruptcy settlement with US government
How to Invest in Meme Penny Stocks in 2022
Endo (ENDP) Files for Bankruptcy Amid Litigations, Huge Debt
Percocet maker Endo International files for bankruptcy
Best Penny Stocks to Buy Now? 3 For Your August List
Endo International Discloses Bankruptcy Possibility In Q2 2022 Results
Endo International (ENDP) Stock Plunges Amid Bankruptcy Warning
Best Penny Stocks to Buy Premarket on August 4th? 3 to Watch
4 Best Penny Stocks To Buy On Reddit According To Options Traders
Endo (ENDP) Inks Deal to Develop Rare Disease Drug in Canada
Why Is Endo International (ENDP) Stock Up Today?
Penny Stocks To Watch: Why KRKR, RMED, TYME, TTNP & ENDP Stock Are Moving
Endo (ENDP) Phase II Study for Frozen Shoulder Disappoints
Why Endo International Shares Are Getting Hammered Today
Endo International (ENDP) Stock Plunges 20% After Missing Interest Payment
Why Endo (ENDP) Stock Wilted After its Surge on Tuesday?
A Guide to How the Stock Market Works
What Is a Stock Split and How Does It Work?